Interaction network among functional drug groups

BackgroundMore attention has been being paid to combinatorial effects of drugs to treat complex diseases or to avoid adverse combinations of drug cocktail. Although drug interaction information has been increasingly accumulated, a novel approach like network-based method is needed to analyse that information systematically and intuitivelyResultsBeyond focussing on drug-drug interactions, we examined interactions between functional drug groups. In this work, functional drug groups were defined based on the Anatomical Therapeutic Chemical (ATC) Classification System. We defined criteria whether two functional drug groups are related. Then we constructed the interaction network of drug groups. The resulting network provides intuitive interpretations. We further constructed another network based on interaction sharing ratio of the first network. Subsequent analysis of the networks showed that some features of drugs can be well described by this kind of interaction even for the case of structurally dissimilar drugs.ConclusionOur networks in this work provide intuitive insights into interactions among drug groups rather than those among single drugs. In addition, information on these interactions can be used as a useful source to describe mechanisms and features of drugs.

[1]  Minho Lee,et al.  Large-scale reverse docking profiles and their applications , 2012, BMC Bioinformatics.

[2]  Lin He,et al.  Exploring Off-Targets and Off-Systems for Adverse Drug Reactions via Chemical-Protein Interactome — Clozapine-Induced Agranulocytosis as a Case Study , 2011, PLoS Comput. Biol..

[3]  Darrell R Abernethy,et al.  Systems pharmacology to predict drug toxicity: integration across levels of biological organization. , 2013, Annual review of pharmacology and toxicology.

[4]  S. Browning,et al.  A Database Analysis of Potentially Inappropriate Drug Use in an Elderly Medicaid Population , 2000, Pharmacotherapy.

[5]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[6]  George S Behonick,et al.  Fentanyl use, misuse, and abuse: a summary of 23 postmortem cases. , 2003, Journal of analytical toxicology.

[7]  M. Forrester Ingestions of Hydrocodone, Carisoprodol, and Alprazolam in Combination Reported to Texas Poison Centers , 2011, Journal of addictive diseases.

[8]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[9]  Yanli Wang,et al.  PubChem: a public information system for analyzing bioactivities of small molecules , 2009, Nucleic Acids Res..

[10]  S. Friend,et al.  A network view of disease and compound screening , 2009, Nature Reviews Drug Discovery.

[11]  David S. Wishart,et al.  DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..

[12]  Inmar E. Givoni,et al.  Exploring the Mode-of-Action of Bioactive Compounds by Chemical-Genetic Profiling in Yeast , 2006, Cell.

[13]  Dongsup Kim,et al.  A novel small molecule facilitates the reprogramming of human somatic cells into a pluripotent state and supports the maintenance of an undifferentiated state of human pluripotent stem cells. , 2012, Angewandte Chemie.

[14]  J. Chen,et al.  Predicting adverse drug reaction profiles by integrating protein interaction networks with drug structures , 2013, Proteomics.

[15]  T Welte,et al.  Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. , 2000, International journal of clinical pharmacology and therapeutics.

[16]  R. Altman,et al.  Informatics confronts drug-drug interactions. , 2013, Trends in pharmacological sciences.

[17]  Francisco Azuaje,et al.  Drug interaction networks: an introduction to translational and clinical applications. , 2013, Cardiovascular research.

[18]  Dongsup Kim,et al.  Construction of the first compendium of chemical-genetic profiles in the fission yeast Schizosaccharomyces pombe and comparative compendium approach. , 2013, Biochemical and biophysical research communications.

[19]  Minho Lee,et al.  FitSearch: a robust way to interpret a yeast fitness profile in terms of drug's mode-of-action , 2013, BMC Genomics.

[20]  A. Butte,et al.  Drug Discovery in a Multidimensional World: Systems, Patterns, and Networks , 2010, Journal of cardiovascular translational research.

[21]  T.-M. Hu,et al.  Architecture of the drug–drug interaction network , 2011, Journal of clinical pharmacy and therapeutics.

[22]  CHUN WEI YAP,et al.  PaDEL‐descriptor: An open source software to calculate molecular descriptors and fingerprints , 2011, J. Comput. Chem..

[23]  P. Bork,et al.  Drug Target Identification Using Side-Effect Similarity , 2008, Science.

[24]  R. Morphy Selectively nonselective kinase inhibition: striking the right balance. , 2010, Journal of medicinal chemistry.

[25]  J. Ebbesen,et al.  Fatal adverse drug events: the paradox of drug treatment , 2001, Journal of internal medicine.

[26]  Xing-Ming Zhao,et al.  The drug cocktail network , 2012, BMC Systems Biology.

[27]  Hongkang Mei,et al.  Systematic Prediction of Pharmacodynamic Drug-Drug Interactions through Protein-Protein-Interaction Network , 2013, PLoS Comput. Biol..

[28]  Gary D. Bader,et al.  An automated method for finding molecular complexes in large protein interaction networks , 2003, BMC Bioinformatics.

[29]  A. Bender,et al.  Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off‐Target Effects from Chemical Structure , 2007, ChemMedChem.